Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial


Paz-Ares L., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., et al.

LANCET, cilt.394, ss.1929-1939, 2019 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 394 Konu: 10212
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/s0140-6736(19)32222-6
  • Dergi Adı: LANCET
  • Sayfa Sayısı: ss.1929-1939

Özet

Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC.